Hemostemix Inc. (CVE:HEM – Get Free Report) shares were up 11.1% during mid-day trading on Friday . The stock traded as high as C$0.05 and last traded at C$0.05. Approximately 63,000 shares changed hands during trading, an increase of 5% from the average daily volume of 59,893 shares. The stock had previously closed at C$0.05.
Hemostemix Stock Up 20.0 %
The firm has a market cap of C$5.23 million, a P/E ratio of -1.67 and a beta of 0.18. The firm has a fifty day moving average of C$0.05 and a 200-day moving average of C$0.06.
Hemostemix Company Profile
Hemostemix Inc, a clinical stage biotechnology company, develops, manufactures, and commercializes blood-derived stem cell therapies for medical conditions. The company develops cell therapy products from the patient's own blood, which is a non-invasive source of therapeutic cells. Its lead product is ACP-01, an autologous cell therapy, which is in Phase II clinical trial for the treatment of vascular diseases, such as cardiovascular disease, peripheral arterial disease, angina pectoris, and ischemia in Canada and the United States.
Recommended Stories
- Five stocks we like better than Hemostemix
- What is MarketRank™? How to Use it
- Lumen: Among Top Performers Last Month, Still Has Warning Signs
- Stock Splits, Do They Really Impact Investors?
- Baidu’s Strong Quarter Proves a Smart Pick for Michael Burry
- About the Markup Calculator
- Intuit Beats Q4 Earnings: AI, Dividends, and a Growth Strategy
Receive News & Ratings for Hemostemix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hemostemix and related companies with MarketBeat.com's FREE daily email newsletter.
